Your support fuels our research to #EndALS! Donate Now
Quick Info
Status
Currently Recruiting
Phase
3
Trial Type
Interventional
Treatment Type
Drug Trials
Randomization
Unkown
Enrollment
150
Start Date
5/17/2021
Sponsor
Contact Information
    Contact information unknown.
Locations
Australia, Other
Research Site, Sydney, 2109, Australia
Belgium, Other
Research Site, Leuven, 3000, Belgium
Brazil, Other
Research Site, São Paulo, 04037-002, Brazil
Canada, Alberta
Research Site, Calgary, AB, T2N 4Z6, Canada
Canada, Ontario
Research Site, Toronto, ON, M4N 3M5, Canada
Canada, Quebec
Research Site, Montréal, QC, H3A 2B4, Canada
France, Other
Research Site, Paris, 75013, France
Germany, Other
Research Site, Hannover, 30625, Germany
Research Site, Ulm, 89081, Germany
Italy, Other
Research Site, Torino, 10126, Italy
Japan, Other
University of Tokyo Hospital, Bunkyo-ku, 113-8655, Japan
Research Site, Kagoshima-shi, 890-8520, Japan
Other, Other
Research Site, Seoul, 4763, Other
Poland, Other
Research Site, Warszawa, 01-684, Poland
Russian Federation, Other
Research Site, Moscow, 125367, Russian Federation
Spain, Other
Research Site, Valencia, 46026, Spain
Sweden, Other
Research Site, Umeå, 90185, Sweden
United Kingdom, Other
Research Site, Sheffield, S10 2HQ, United Kingdom
United States, Arizona
Research Site, Scottsdale, AZ, 85251, United States
United States, California
Research Site, La Jolla, CA, 92037, United States
California Pacific Medical Center, San Francisco, CA, 94109, United States
Contact: Ryan Razavi   415-600-0486   razavirf@sutterhealth.org
United States, Florida
Holy Cross Hospital Phil Smith Neuroscience Institute, Fort Lauderdale, FL, 33308, United States
Contact: Donovan Mott   954-542-3442   donovan.mott@holy-cross.com
University of Miami, Miami, FL, 33136, United States
Contact: Anne-Laure Grignon   axg1571@med.miami.edu
United States, Georgia
Emory University, Atlanta, GA, 30322, United States
Contact: Meraida Polak   404-778-3807   mpolak@emory.edu
United States, Illinois
Research Site, Chicago, IL, 60611, United States
United States, Maryland
Johns Hopkins Hospital, Baltimore, MD, 21287, United States
United States, Massachusetts
Massachusetts General Hospital, Boston, MA, 02114, United States
United States, Missouri
Washington University School of Medicine, Saint Louis, MO, 63110, United States
Contact: Dr Robert Bucelli   844-257-2273   als@wustl.edu
United States, New York
Research Site, New York, NY, 10032, United States
United States, Texas
Austin Neuromuscular Center, Austin, TX, 78756, United States
Contact: Yessar Hussain   yessar@austinneuromuscle.com
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
N/A
Months Since Onset
Number of months since first symptoms of ALS.
N/A
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
N/A
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
N/A
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Not Available
Open Label
Yes
Update Notes
Sites added
9/24/2021
Protocol updates, new sites added
8/12/2021
New site added
7/13/2021
New site added
7/9/2021
New site added
7/6/2021
Site contacts updated
6/16/2021
Study recruiting
6/9/2021
Study added
4/26/2021

Other Information

Purpose
The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB067 and to evaluate the effect of BIIB067 on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).
Eligibility
Key Part A Inclusion Criteria:
- Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an external mutation adjudication committee.
- Participants with plasma NfL level less than the protocol-defined threshold.
- Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifest ALS).
Key Part A Exclusion Criteria:
- History or positive test result at screening for human immunodeficiency virus (HIV).
The requirement for testing at Screening may be omitted if it is not permitted by local regulations.
- Current hepatitis C infection (defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV RNA). Participants with positive HCV antibody and undetectable HCV Ribonucleic Acid (RNA) are eligible to participate in the study (United States Centers for Disease Control and Prevention).
- Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study.
- History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.
- History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator.
- Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding.
- Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression ≤ 90 days of screening, which in the opinion of the Investigator would interfere with the study procedures.
- Treatment with riluzole and/or edaravone. If the participant has been on riluzole and/or edaravone, the medication(s) must be discontinued for at least 5 half-lives prior to screening.
- Use of off-label treatments for ALS.
- Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.
- Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for an LP procedure, if necessary, according to local or institutional guidelines and/or Investigator determination.
- Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator.
NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.
Details
Collaborator(s)
  • Biogen
Trial Protocol as Published on Clinicaltrials.gov
NCT04856982 (First Published: 4/20/2021)